These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 35600209)

  • 1. Glucocorticosteroids and the Risk of NAFLD in Inflammatory Bowel Disease.
    Jarmakiewicz-Czaja S; Sokal A; Pardak P; Filip R
    Can J Gastroenterol Hepatol; 2022; 2022():4344905. PubMed ID: 35600209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intestinal Inflammation Does Not Predict Nonalcoholic Fatty Liver Disease Severity in Inflammatory Bowel Disease Patients.
    Carr RM; Patel A; Bownik H; Oranu A; Kerner C; Praestgaard A; Forde KA; Reddy KR; Lichtenstein GR
    Dig Dis Sci; 2017 May; 62(5):1354-1361. PubMed ID: 28265826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evaluation of liver abnormalities in inflammatory bowel disease patients.
    McHenry S
    Curr Opin Gastroenterol; 2023 Jul; 39(4):287-293. PubMed ID: 37144524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Disease: Prevalence and Risk Factors.
    Principi M; Iannone A; Losurdo G; Mangia M; Shahini E; Albano F; Rizzi SF; La Fortezza RF; Lovero R; Contaldo A; Barone M; Leandro G; Ierardi E; Di Leo A
    Inflamm Bowel Dis; 2018 Jun; 24(7):1589-1596. PubMed ID: 29688336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crohn´s disease is an independent risk factor for liver fibrosis in patients with inflammatory bowel disease and non-alcoholic fatty liver disease.
    Martínez-Domínguez SJ; García-Mateo S; Gargallo-Puyuelo CJ; Gallego Llera B; Refaie E; Callau P; Mendi C; Baptista PM; Hernández Ainsa M; Arroyo-Villarino MT; López de la Cruz J; Martínez-García J; Alfambra E; Simón Marco MÁ; Ampuero J; Gomollón F
    Eur J Intern Med; 2024 Feb; 120():99-106. PubMed ID: 37872034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease.
    Sourianarayanane A; Garg G; Smith TH; Butt MI; McCullough AJ; Shen B
    J Crohns Colitis; 2013 Sep; 7(8):e279-85. PubMed ID: 23158500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory Bowel Disease-associated Fatty Liver Disease: the Potential Effect of Biologic Agents.
    Papaefthymiou A; Potamianos S; Goulas A; Doulberis M; Kountouras J; Polyzos SA
    J Crohns Colitis; 2022 Jun; 16(5):852-862. PubMed ID: 34972203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of NAFLD on Hospitalization Outcomes in Patients With Inflammatory Bowel Diseases: Nationwide Analysis.
    Noorian S; Jeon Y; Nguyen MT; Sauk J; Limketkai BN
    Inflamm Bowel Dis; 2022 Jun; 28(6):878-887. PubMed ID: 34374782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic Steatosis but Not Fibrosis Is Independently Associated with Poor Outcomes in Patients with Inflammatory Bowel Disease.
    Hyun HK; Lee HW; Park J; Park SJ; Park JJ; Kim TI; Lee JS; Kim BK; Park JY; Kim DY; Ahn SH; Kim SU; Cheon JH
    Gut Liver; 2024 Mar; 18(2):294-304. PubMed ID: 37203442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease.
    Bessissow T; Le NH; Rollet K; Afif W; Bitton A; Sebastiani G
    Inflamm Bowel Dis; 2016 Aug; 22(8):1937-44. PubMed ID: 27379445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: Beyond the natural history.
    Magrì S; Paduano D; Chicco F; Cingolani A; Farris C; Delogu G; Tumbarello F; Lai M; Melis A; Casula L; Fantini MC; Usai P
    World J Gastroenterol; 2019 Oct; 25(37):5676-5686. PubMed ID: 31602167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Steroid Use and Risk of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: Systematic Review and Meta-analysis.
    Trivedi HD; Lopes EW; Glissen Brown J; Dudani S; Lai M; Feuerstein JD; Pierce TT
    J Clin Gastroenterol; 2023 Jul; 57(6):610-616. PubMed ID: 35648974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of inflammatory bowel disease treatment on the risk of nonalcoholic fatty liver disease: a meta-analysis.
    Lapumnuaypol K; Kanjanahattakij N; Pisarcik D; Thongprayoon C; Wijarnpreecha K; Cheungpasitporn W
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):854-860. PubMed ID: 29697458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic Review and Meta-Analysis: Prevalence of Non-Alcoholic Fatty Liver Disease and Liver Fibrosis in Patients with Inflammatory Bowel Disease.
    Navarro P; Gutiérrez-Ramírez L; Tejera-Muñoz A; Arias Á; Lucendo AJ
    Nutrients; 2023 Oct; 15(21):. PubMed ID: 37960160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease Among Patients with Inflammatory Bowel Disease.
    Glassner K; Malaty HM; Abraham BP
    Inflamm Bowel Dis; 2017 Jun; 23(6):998-1003. PubMed ID: 28511199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic Review With Meta-analysis: Epidemiology of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease.
    Zou ZY; Shen B; Fan JG
    Inflamm Bowel Dis; 2019 Oct; 25(11):1764-1772. PubMed ID: 30918952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps.
    Santos RD; Valenti L; Romeo S
    Atherosclerosis; 2019 Mar; 282():110-120. PubMed ID: 30731283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sarcopenia Is a New Risk Factor of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Disease.
    Kang MK; Kim KO; Kim MC; Park JG; Jang BI
    Dig Dis; 2020; 38(6):507-514. PubMed ID: 32135539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography.
    Saroli Palumbo C; Restellini S; Chao CY; Aruljothy A; Lemieux C; Wild G; Afif W; Lakatos PL; Bitton A; Cocciolillo S; Ghali P; Bessissow T; Sebastiani G
    Inflamm Bowel Dis; 2019 Jan; 25(1):124-133. PubMed ID: 29889226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multifaceted pathogenesis of liver steatosis in inflammatory bowel disease: a systematic review.
    Spagnuolo R; Abenavoli L; Corea A; Larussa T; Mancina RM; Cosco C; Luzza F; Doldo P
    Eur Rev Med Pharmacol Sci; 2021 Sep; 25(18):5818-5825. PubMed ID: 34604973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.